

Factors which impact on the response of CML patients to ABL kinase inhibitor therapy: A study of imatinib and nilotinib.

Deborah Lee Harland
(nee White)

The Melissa White Laboratory
Hanson Institute and
Institute of Medical & Veterinary Science
&
The Faculty of Health Science
Department of Medicine
The University of Adelaide
South Australia

Thesis submitted to the University of Adelaide
in candidature for the degree of Doctor of Philosophy
April 2008

TABLE OF CONTENTS

Factors which impact on the response of CML patients to ABL kinase inhibitor therapy: A study of imatinib and nilotinib.	I
<i>TABLE OF CONTENTS</i>	<i>I</i>
<i>TABLE OF FIGURES</i>	<i>VI</i>
<i>Manuscript Tables</i>	<i>IX</i>
<i>DECLARATION</i>	<i>X</i>
<i>GLOSSARY</i>	<i>XIV</i>
<i>Clinical Trials Referred to in this Thesis</i>	<i>XVII</i>
<i>Abstract</i>	<i>XVIII</i>
Chapter 1	1
<i>Introduction</i>	<i>1</i>
<i>1.1 Chronic Myeloid Leukaemia</i>	<i>2</i>
1.1.1 The Philadelphia Chromosome and BCR-ABL protein	2
1.1.2 Downstream effects of the BCR-ABL oncoprotein	6
<i>1.2 Treatment Options for patients with CML.</i>	<i>9</i>
1.2.1 Allogeneic Transplantation	9
1.2.2 Autologous Transplantation	9
1.2.3 Conventional and intensive chemotherapy	9
1.2.4 Interferon	10
<i>1.3 Tyrosine Kinase Inhibitor Therapy</i>	<i>10</i>
1.3.1 Imatinib mesylate (Gleevec, Glivec, STI571 and CGP571488)	11
1.3.2 Imatinib mesylate: Mechanism of action	13
<i>1.4 Imatinib mesylate: Efficacy</i>	<i>13</i>
1.4.1 Phase I, II and III clinical Studies	13
<i>1.5 Imatinib resistance</i>	<i>16</i>
<i>1.6 Second generation kinase inhibitors</i>	<i>18</i>
<i>1.7 Monitoring patient response to ABL kinase inhibitor therapy</i>	<i>19</i>
<i>1.8 Research of the Author</i>	<i>22</i>
Chapter 2	24
<i>The development of an in-vitro assay to predict imatinib response pre-therapy.</i>	<i>24</i>
<i>2.1 Introduction</i>	<i>25</i>
<i>2.2 Historical parameters used to predict response and their applicability in the imatinib era.</i>	<i>25</i>
2.2.1 Patient Age	25
2.2.2 Variant Ph chromosome	25
2.2.3 Deletions of derivative chromosome 9	25
2.2.4 Sokal and Hasford scores	26
<i>2.3 New prognostic models – imatinib treated patients</i>	<i>27</i>
2.3.1 Factors impacting on the achievement of a Major Cytogenetic Response (MCyR)	27
2.3.2 Imatinib drug levels and predicting response	27

2.3.3	Early molecular response and the prediction of long term response	28
2.4	<i>Summary and research contribution</i>	29
	Publications	29
	Conference Presentations.	29
2.5	<i>Assay development: Background and results.</i>	30
2.5.1	Crkl as a surrogate marker for BCR-ABL kinase activity.	30
2.5.2	Assay development and prediction of molecular response(White et al. 2005a).	33
2.6	<i>Results (White et al. 2005a).</i>	36
2.6.1	The IC50 ^{imatinib} and prediction of subsequent molecular response.	36
2.6.2	Association of IC50 ^{imatinib} with other pre-therapy prognostic indicators(White et al. 2005a; White Deborah et al. 2004)	36
2.6.3	Chromosome 9 deletions	40
2.6.4	Association of IC50 ^{imatinib} with early molecular response (EMR)(White et al. 2005b)	44
2.7	<i>Summary of initial analysis</i>	44
2.8	<i>Subsequent analysis</i>	50
2.9	<i>Overall Conclusion from this body of data.</i>	52
Chapter 3		53
	<i>Development of an early treatment phase, in-vivo assay to predict long term molecular response in patients treated with imatinib.</i>	53
3.1	<i>Introduction</i>	54
3.2	<i>Summary and research contribution</i>	55
	Publications	55
	Conference Presentations	55
3.3	<i>Assay development: Background and Methodology</i>	56
3.3.1	Background	56
3.3.2	Patient cohort	56
3.3.3	Method	56
3.3.4	Assay Reproducibility.	57
3.4	<i>Results</i>	63
3.4.1	First Analysis (presented at ASH 2005) (White et al. 2005a)	63
3.5	<i>Summary – Initial Analyses</i>	73
3.6	<i>Subsequent Analyses (White et al. 2007a)</i>	73
3.6.1	Rationale	73
3.6.2	Results	73
3.6.2.4	Is the reduction in p-Crkl merely a reflection of the normalisation of blood leukocyte parameters?	85
3.7	<i>Summary</i>	91
3.8	<i>Overall Conclusion</i>	92
Chapter 4		93
	<i>Investigation of the intracellular transport mechanism of imatinib</i>	93
4.1	<i>Introduction</i>	94
4.2	<i>Summary and research contribution</i>	96
	Publications	96
	Conference Presentations.	96
4.3	<i>Assay development</i>	97
4.3.1	Background	97
4.3.2	Intracellular Uptake and Retention (IUR) Assay	98
4.3.3	Flow cytometric assessment of Efflux Proteins.	99

4.3.4	IC ₅₀ ^{imatinib} assay	99
4.4	<i>Results</i>	101
4.4.1	Correlation between IC ₅₀ ^{imatinib} and IUR	101
4.4.2	Effect of temperature of IUR of imatinib	101
4.4.3	The effect of OCT inhibitors on the IUR of imatinib	105
4.4.4	Effect of the OCT inhibitors on the IC ₅₀ ^{imatinib} .	109
4.4.5	Implication of the expression of ABCB1 on the transport of imatinib.	109
4.4.6	Implications of ABCG2 on the transport of imatinib.	110
4.4.7	Correlation between IUR imatinib and molecular outcome.	110
4.5	<i>Assay Control</i>	114
4.6	<i>Summary</i>	117
4.7	<i>Overall comment on significance of this work</i>	118
Chapter 5		119
	<i>Investigation of the intracellular transport mechanism of nilotinib</i>	119
5.1	<i>Introduction</i>	120
5.2	<i>Summary and research contribution</i>	121
	Publications	121
	Conference Presentations.	121
5.3	<i>Assay development</i>	123
5.3.1	Intracellular Uptake and Retention (IUR) Assay	123
5.3.2	The IC ₅₀ ^{nilotinib} assay.	123
5.3.3	Drugs and Inhibitors	123
5.3.4	Flow cytometry and western blot analysis for determining the IC ₅₀ ^{nilotinib}	123
5.3.5	Patient samples and cell lines	123
5.4	<i>Results</i>	124
5.4.1	Correlation between IC ₅₀ ^{nilotinib} and IC ₅₀ ^{imatinib} .	124
5.4.2	Correlation between IC ₅₀ ^{nilotinib} and the IUR for nilotinib.	124
5.4.3	The effect of temperature on the IUR of nilotinib.	126
5.4.4	Effect of influx inhibitors on the IUR of nilotinib and IC ₅₀ ^{nilotinib} .	126
5.4.5	The role of efflux proteins in nilotinib transport.	133
5.5	<i>Assay Control and Quality Control</i>	142
5.6	<i>Summary.</i>	144
5.7	<i>Comment on significance of this work</i>	146
Chapter 6		147
	<i>The interaction of imatinib and nilotinib in drug combination studies.</i>	147
6.1	<i>Introduction</i>	148
6.2	<i>Summary and research contribution</i>	150
	Publications	150
	Conference Presentations.	150
6.3	<i>Assay development</i>	151
6.3.1	Intracellular Uptake and Retention (IUR) Assay	151
6.3.2	Drugs and inhibitors	151
6.3.3	Patient samples and cell lines	152
6.3.4	Cell viability	152
6.4	<i>Results</i>	154
6.4.1	The effect of cold imatinib on the IUR for [14C]- nilotinib	154
6.4.2	The effect of cold nilotinib on the IUR for [14C]- imatinib	154
6.4.3	Comparison of the effect of combination therapy on the intracellular concentration of both drugs.	155

6.4.4	Cell lines	155
6.4.5	Cell viability	159
6.6	<i>Overall comment on significance of this work</i>	174
Chapter 7:		175
	<i>The effect of proton pump inhibitors on the intracellular accumulation of imatinib and nilotinib</i>	175
7.1	<i>Introduction</i>	176
7.2	<i>Summary and research contribution</i>	179
	Conference Presentations.	179
7.3	<i>Assay development</i>	180
7.3.1	Intracellular Uptake and Retention (IUR) Assay	180
7.3.2	Patient samples and cell lines	180
7.3.3	Cell viability	180
7.4	<i>Results</i>	183
7.4.1	The effect of pantoprazole on the IUR of imatinib	183
7.4.2	The effect of esomeprazole on the IUR of imatinib	186
7.4.3	The effect of pantoprazole on the IUR of nilotinib	186
7.4.4	The effect of esomeprazole on the IUR of nilotinib	186
7.4.5	Comparison of the effects of pantoprazole and esomeprazole on the intracellular concentration of both imatinib and nilotinib.	187
7.4.6	Effect of PPI on the IC ₅₀ for nilotinib and imatinib.	198
7.4.7	The effect of low dose PPI on the IUR of imatinib and nilotinib.	198
7.4.8	Effect of low dose pantoprazole on the IC ₅₀ for imatinib and nilotinib.	198
7.4.9	The affect of PPI on the uptake of imatinib.	199
7.4.10	Cell viability	199
7.5	<i>Summary</i>	209
7.6	<i>Overall Comment and significance of this work</i>	211
Chapter 8		212
	<i>The Functional Activity of the human Organic Cation Transporter – 1 (hOCT-1) Protein</i>	212
8.1	<i>Introduction</i>	213
8.2	<i>Summary and research contribution</i>	215
	Publications	215
	Conference Presentations.	215
8.3	<i>Assay development</i>	216
8.3.1	Intracellular Uptake and Retention (IUR) Assay	216
8.3.2	IC ₅₀ ^{imatinib} assay	216
8.3.3	OCT-1 mRNA levels.	216
8.4	<i>Results</i>	217
8.4.1	OCT-1 Activity	217
8.4.2	The Intracellular uptake and retention of imatinib (IUR) and the IC ₅₀ ^{imatinib} .	217
8.4.3	OCT-1 Activity and IC ₅₀ ^{imatinib}	217
8.4.4	OCT-1 Activity and Sokal Prognostic Score.	220
8.4.5	OCT-1 Activity, molecular response and the effect of actual dose received.	220
8.4.6	Effect of dose increase	226
8.4.7	OCT-1 Activity, Suboptimal response and imatinib failure	228
8.4.8	OCT-1 mRNA and OCT-1 Activity	228
8.4.9	BCR-ABL kinase domain mutations and OCT-1 Activity	237
8.4.10	Patients with negligible OCT-1 Activity	237
8.5	<i>Summary</i>	238
8.6	<i>Overall Comment and significance of this work</i>	241

Chapter 9	242
<i>Summary</i>	242
Appendix I:	254
<i>Materials and Methods</i>	254
I.2 <i>Commonly used Reagents</i>	257
1.2.1 Cell culture media	257
1.2.2 Imatinib mesylate, MW = 589.72	257
1.2.3 Nilotinib, MW = 529.5	257
1.2.4 50% Mixture of hot and cold imatinib, 100 μ M – for 1 mL :	257
1.2.5 50% Mixture of hot and cold nilotinib, 10 μ M – for 1 mL :	257
1.2.6 Flow Cytometry Fixative (FACS Fixative)	258
1.2.7 Freeze Mix	258
1.2.8 Thaw Solution	258
1.2.9 White Cell Fluid	258
1.2.10 Hanks Balanced Salt Solution (HBSS)	258
1.2.11 Laemmli's Buffer	259
1.2.12 1 x TBS	259
1.2.13 1 x TBST	259
1.2.14 dNTP set (N = A, C, G, T)	259
1.2.15 Random Hexamer Primer (100 μ g stock)	259
1.2.16 Prazosin - inhibits OCT-1	259
1.2.17 PSC833 – inhibits ABCB1/MDR	260
1.2.18 Procainamide – inhibits OCT-1 and OCT-2	260
1.2.19 Ko143 – inhibits ABCG2/BCRP1	260
I.3 <i>General techniques.</i>	261
1.3.1 Lymphoprep isolation of mononuclear cells	261
1.3.2 Cryopreservation of cells	261
1.3.3 Thawing of cells	261
1.3.4 Cell counts and viability	261
1.3.5 Maintenance of cell lines	262
I.4 <i>Specialised Techniques</i>	263
1.4.1 IC50 Assay (In-vitro kinase inhibition assay)	263
1.4.2 In-vivo kinase inhibition assay.	265
1.4.3 Imatinib/nilotinib IUR assay	265
1.4.4 Immunophenotyping for ABCB1 and ABCG2 expression	266
1.4.5 mRNA isolation	267
1.4.6 cDNA synthesis	267
1.4.7 PCR for OCT-1 mRNA Expression	268
I.5 <i>Computer Software Required.</i>	269
I.6 <i>Laboratory Equipment Required</i>	269
Appendix II:	270
<i>References</i>	270
Appendix II- References	271
Appendix III:	309
<i>Publications arising from the Thesis</i>	309

TABLE OF FIGURES

Figure 1.1	The formation of the Philadelphia chromosome	4
Figure 1.2	The formation of the BCR-ABL gene leads to deregulation of normal signal transduction pathways.	5
Figure 1.3	The function of the fusion protein p210 ^{BCR-ABL}	8
Figure 1.4	Chemical structure of imatinib mesylate	12
Figure 1.5	IRIS trial 5 year update demonstrating the % of patients achieving CHR, MCyR and CCyR.	15
Figure 1.6	The probability of detecting a mutation by 24 months of imatinib therapy determined for each CML disease phase.....	17
Figure 1.7	The Chemical Structure of nilotinib.....	20
Figure 1.8	Chemical Structure of dasatinib	21
Figure 2.1	The structure and down stream interactions of Crkl.....	32
Figure 2.2	Stages of the imatinib IC ₅₀ assay (K562 cells)	34
Figure 2.3	The interpatient variation in the IC ₅₀ ^{imatinib} was high in CP CML patients.....	37
Figure 2.4	Demonstrating various IC ₅₀ ^{imatinib} western blots.....	38
Figure 2.5	Kaplan-Meier graphs demonstrating the percentage of patients predicted to achieve 2-log reduction by 3 months and 3-log reduction (MMR) by 12months.	39
Figure 2.6	Dot plot comparing the IC ₅₀ ^{imatinib} with the Sokal Prognostic Score.....	41
Figure 2.7	Assessment of factors which may predict for the achievement of MMR.	46
Figure 2.8	The difference in median log reduction at 3 and 6 months between those patients who achieve MMR and those who fail to.....	48
Figure 2.9	The percentage of patients achieving MMR by 24 months based on low and high IC ₅₀ ^{imatinib} groups.	51
Figure 3.1	Sample preparation guidelines for preparation of in-vivo protein lysates.	58
Figure 3.2 I, II and III	Examples of in-vivo kinase inhibition assay.....	59
Figure 3.2 II	60
	Samples from this patient were collected at days 0, 6 and 20. There was a 36% decrease in the level of p-Crkl by day 6, but no significant further reduction by day 20.	60
Figure 3.2 III	61
Figure 3.3	Demonstration of the correlation between the level of p-Crkl in two independently prepared lysates.	62
Figure 3.4	The percentage of p-Crkl observed in blood collected at 7 day intervals from 49 patients enrolled to the TIDEL trial.	66
Figure 3.5	The percentage of patients achieving MMR by 24 months based on % reduction in p-Crkl over the first 14 days of imatinib therapy.....	68
Figure 3.6	The percentage of patients achieving MMR by 24 months based on % kinase inhibition achieved from days 21 to 28.	69
Figure 3.7	The percentage of patients achieving MMR by 24 months based on % kinase inhibition achieved from days 21 to 28 where the analysis was limited to only those patients receiving ≥ 540 mg per day (90%of prescribed dose).....	70
Figure 3.8	A high in-vivo kinase inhibition is associated with a low IC ₅₀ ^{imatinib}	71
Figure 3.9	The percentage of patients achieving MMR by 24 months based on % kinase inhibition achieved from days 21 to 28, where the analysis was limited to only those patients with low IC ₅₀ ^{imatinib}	72
Figure 3.10	Comparison between Sokal Score and the degree of kinase inhibition achieved by day 28.	78
Figure 3.11	Comparison between log reduction achieved at 1 month and the degree of kinase inhibition achieved by day 28.....	79
Figure 3.12	Correlation between IC ₅₀ ^{imatinib} and % kinase inhibition by day 28.....	83
Figure 3.13	Patients were grouped according to the achievement of 50% kinase inhibition or not and relevant IC ₅₀ ^{imatinib} were plotted against these groups.....	84
Figure 3.14	Assessment of early treatment phase blood parameters contributing to achievement of MMR.....	87
Figure 3.15	Assessment of quartiles of the degree of kinase inhibition achieved on subsequent molecular response	89
Figure 3.16	The time to achieve 50% kinase inhibition, within the first month of therapy, is not a significant determinant of MMR by 24 months.....	90
Figure 4.1	The Human Organic Transporter – 1 (hOCT-1).....	100
Figure 4.2	Comparison of the IC ₅₀ ^{imatinib} and the intracellular uptake and retention (IUR) of [14C] imatinib.	102
Figure 4.3	Comparison of the IC ₅₀ ^{imatinib} and the intracellular uptake and retention (IUR) of [14C] imatinib.	103

Figure 4.4	Box plots demonstrating the difference in IUR (at 2 μ M imatinib) between high and low IC50 ^{imatinib} groups.....	104
Figure 4.5	Box plots demonstrating the difference in IUR (at 2 μ M imatinib) between high and low IC50 ^{imatinib} groups, and the effect of the addition of Prazosin to these groups.....	106
Figure 4.6	The effect of OCT-1 inhibitors on the IC50 ^{imatinib} in K562 cells.....	111
Figure 4.7	FACS Histograms showing the expression of ABCB1 and ABCG2 on VBL100 cells and CCRF-CEM cells.....	112
Figure 4.8	FACS Histograms demonstrating the expression of ABCG2 and ABCB1 in Mef 3.8 and Mef-BCRP1 cell lines.....	113
Figure 4.9	Quality Control Curves for A Intracellular uptake and retention (IUR) and B IUR + Prazosin.....	115
Figure 5.1	Comparative chemical structures of imatinib and nilotinib.....	122
Figure 5.2	Comparison between the IC50 ^{imatinib} and IC50 ^{nilotinib} in 72 chronic phase CML patients.....	125
Figure 5.3.	Comparison of IC50 ^{nilotinib} with the IUR of nilotinib.....	128
Figure 5.4	Assessment of the IUR of low and high IC50 groups with and without prazosin.....	131
Figure 5.5	The effect of prazosin on the IC50 ^{nilotinib}	136
Figure 5.6	The effect of ABCB1 expression on nilotinib IUR.....	138
Figure 5.7	Western Blot of K562 DOX cells (ABCB1 over expressing) demonstrating the difference in the IC50 ^{nilotinib} in the presence and absence of PSC833.....	139
Figure 5.8	Assessing the IUR of nilotinib in K562DOX cells with and without the ABCB1 inhibitor PSC833.....	141
Figure 5.9	K562 Quality Control Graph for IUR Nilotinib.....	143
Figure 6.1	The effect of unlabelled imatinib on the intracellular concentration of 1 μ M and 2 μ M [14C] labelled nilotinib.....	156
Figure 6.2	The percentage increase in the IUR for nilotinib in the presence of unlabelled imatinib.....	158
Figure 6.3	The effect of unlabelled nilotinib on the IUR of 1 μ M and 2 μ M [14C] labelled imatinib.....	160
Figure 6.4	The percentage decrease in the IUR for imatinib at 1 and 2 μ M in the presence of unlabelled nilotinib.....	162
Figure 6.5	Comparing of the effect of combination therapy on the intracellular concentration of both imatinib and nilotinib.....	163
Figure 6.6	The effect of combination therapy in the ABCB1 over expressing cell line K562-DOX.....	166
Figure 6.7	The effect of combination therapy in the ABCG2 over expressing cell line Mef BCRP1 and the parental line Mef 3.8.....	168
Figure 6.8	Possible interactions of imatinib and nilotinib with ABC transporters.....	169
Figure 7.1	Chemical structure and chemical name for Pantoprazole and Esomeprazole.....	178
Figure 7.2	The effect of the addition of pantoprazole on the intracellular concentration of imatinib.....	184
Figure 7.3	The percentage change in the intracellular concentration for imatinib in the presence of pantoprazole.....	185
Figure 7.4	The effect of esomeprazole on the intracellular concentration of imatinib.....	188
Figure 7.5	The percentage change in the intracellular concentration of imatinib in the presence of esomeprazole.....	189
Figure 7.6	The effect of pantoprazole on the intracellular concentration of nilotinib.....	190
Figure 7.7	The percentage change, from no imatinib control, in the intracellular concentration of nilotinib, when pantoprazole was added.....	191
Figure 7.8	The effect of esomeprazole on the intracellular concentration of nilotinib.....	192
Figure 7.9	The percentage change, from no esomeprazole control, in the intracellular concentration of nilotinib, when esomeprazole is added.....	193
Figure 7.10	The overall effect of both pantoprazole and esomeprazole on the IUR of both imatinib and nilotinib.....	194
Figure 7.11	Comparison of the effect on the intracellular concentrations of nilotinib and imatinib with the addition of pantoprazole and esomeprazole (PPI).....	196
Figure 7.12	Effect of Esomeprazole at 200 μ M on the IC50 ^{imatinib} and IC50 ^{nilotinib} in K562 cells.....	200
Figure 7.13	Effect of esomeprazole and pantoprazole at 200 μ M on the IC50 ^{nilotinib} in K562DOXcells.....	201
Figure 7.14	Effect of esomeprazole and pantoprazole at 200 μ M on the IC50 ^{imatinib} in K562DOXcells.....	202
Figure 7.15	Effect of pantoprazole at 200 μ M on the IC50 for imatinib and nilotinib in patient cells.....	205
Figure 7.16	Effect of low dose pantoprazole (25 μ M) on the IC50 for imatinib and nilotinib in K562 and K562DOX cells.....	206
Figure 7.17	Effect of pantoprazole and esomeprazole on the intracellular concentration of imatinib assessed as total, prazosin not inhibited and prazosin inhibit able uptake.....	207

Figure 8.1	Comparison between the OCT-1 Activities defined by the OCT-1 inhibitors prazosin and procainamide.	218
Figure 8.2	Correlation analysis reveals a link between the $IC_{50}^{imatinib}$ and the OCT-1 Activity for imatinib ...	219
Figure 8.3	X-Y plot, demonstrating the lack of correlation between the OCT-1 Activity for imatinib and the Sokal Prognostic Score.	222
Figure 8.4	Kaplan Meier analysis showing the % of patients achieving a major molecular response (MMR) based on low and high OCT-1 Activity groups.	225
Figure 8.5	The variable effect of dose increase, on molecular response after 12 months, in patients grouped as having either high or low OCT-1 Activity.	227
Figure 8.6	The OCT-1 Activity compared to molecular responses (log reduction in BCR-ABL) at 18 months.	230
Figure 8.7	The OCT-1 Activity is compared to the level of OCT-1 mRNA in 93 CML patients	233
Figure 8.8	There was no demonstrable correlation between the $IC_{50}^{imatinib}$ and the level of OCT-1 mRNA. ...	234
Figure 9.1.	Intracellular concentration, OCT-1 Activity and their effect on the intrinsic sensitivity to imatinib induced kinase inhibition.	245
Figure 9.2	Nilotinib transport mechanism.	252

Manuscript Tables

Table 2.1	The Sokal Score and prediction of subsequent molecular response	42
Table 2.2	The Sokal Score and prediction of subsequent molecular response, in the cohort of patients with low IC50 ^{imatinib} only.	43
Table 3.1	The median and range of %p-Crkl at each analysed timepoint for the patient cohort.	65
Table 3.2	The percentage of patients achieving optimal and sub-optimal responses based on low and high in-vivo kinase inhibition (dichotomised about the median) to days 21-28.	67
Table 3.3	Proportion of patients failing to achieve, or achieving various imatinib response criteria	75
Table 3.4	The proportion of patients achieving various imatinib response criteria based on 1 month PCR data and Sokal score.....	77
Table 3.5	Comparison of the predictive value of early molecular response and kinase inhibition achieved. .	81
Table 4.1	The effect of specific influx and efflux inhibitors on IUR of imatinib on the total patient pool, and in the low and high IC50 ^{imatinib} cohorts	107
Table 5.1	The intracellular concentration of nilotinib in low and high IC50 ^{nilotinib} patient groups.	129
Table 5.2	Comparison of the IUR of nilotinib when assays are performed at 4°C and 37°C.	130
Table 5.3	The effect of various transport inhibitors of the IUR of nilotinib at 2µM.....	135
Table 6.1	Schema for the addition of drugs to assess the effect of combination.....	153
Table 6.2	The effect of combination therapy on the IUR of labelled drugs in cell lines.	165
Table 7.1	Schema for the addition of drugs imatinib/nilotinib and PPI to assess the effect of the combination.	181
Table 7.2	The effect of low dose pantoprazole on the intracellular concentration of imatinib and nilotinib.	203
Table 8.1	Assessing the impact of OCT-1 Activity on molecular response in 56 patients enrolled to the TIDEL trial	223
Table 8.2	Percentage of patients failing to achieve previously defined (Baccarani et al. 2006) sub-optimal response criteria.	232
Table 8.3	Assessing the impact of the level of OCT-1 mRNA on molecular response	235
Table 8.4	Percentage of patients failing to achieve previously defined (Baccarani et al. 2006) sub-optimal response criteria, based on the level of OCT-1 mRNA.	236
Table I.1	Suppliers of commonly used reagents.....	255
Table I.2	Imatinib /AMN107(nilotinib) Titrations.....	264
Table I.3:	Commonly used antibody volumes.....	267
Table I.4	First Strand Synthesis Reagent Mix.....	268
Table I.5	Primers are diluted to a working stock of 100 ng/µl in DEPC water.....	268
Table I.6	Preparation of PCR Master mix.	269
Table I.7	Profile Settings for Rotor Gene.....	269

DECLARATION

This thesis contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text.

I give consent to this copy of my thesis, when deposited in the University Library, being available for loan and photocopying.

Deborah Harland (nee White)

8th Day of April 2008

ACKNOWLEDGEMENTS

I recently had cause to interview prospective PhD students. One of these students asked me what I felt were “critical components” of a successful PhD. My answer “Firstly, you need to have a real passion for your topic. Secondly, you need to have a supervisor who shares this enthusiasm, and finally you need to have a strong support network of family and friends”. I was sincerely lucky, I had all three of these things, and more....

First of all, I would like to thank my principal supervisor Professor Tim Hughes, who encouraged me to do a PhD, and provided tireless help and support throughout. Whenever I thought things were heading for a dead-end Tim always wandered in with a “why don’t you try analysing the data this way....?” My early PhD nightmares started with “Why don’t you try analysing the data....”. It didn’t take long to realise that it was these words that helped keep my project alive! For all this, and more, I sincerely thank you, Tim. I also would like to thank my co-supervisor Dr Andrew Zannettino for his tireless efforts, insightful suggestions and for taking the time to read this Thesis word by word, and missing comma by missing comma! Many of the scribbled margin comments kept me smiling... and Yes Andrew I have heard of A, B and C! Seriously, your broad scientific knowledge added an invaluable depth to this project, and for this I am sincerely grateful.

I would also like to acknowledge the assistance of several of the Research Assistants within our lab. Phuong Dang, Amity Frede, Laura Eadie, Steph Zrim and Jane Engler (now PhD Student) are a talented “bunch” of dedicated RA’s who were always willing to help out. Also to Bron Cambareri and Sasha Wheeler for their administrative help in keeping the lab “organised” when it all got beyond me, and to Dr David Ross, Dr Devendra Hiwase and Stephen Blake, fellow PhD students, who always provided valuable comments. A person I can’t thank enough is Verity Saunders. The most talented RA I have ever had the pleasure to work with, without whom the lab would have imploded while I was occupied “doing PhD things”. Without Verity, I never would have been able to complete the writing of this Thesis. Many thanks also go to Dr Peter Diamond for his help with PCR, and to Dr Tony Cambareri for being so tolerant of my formatting “issues”, and for fixing manuscript diagrams, and showing sufficient restraint, so as not to tell me what he really thought! I would also like to thank Professor Bik To for his ongoing support and encouragement. I still remember his excitement for, and with me, when my first Blood paper was accepted.

We have indeed been fortunate in our lab, not just because of the great staff, and support network within the IMVS, but because of the external support we also receive. I am sincerely indebted to Dr Kevin Lynch, Helen Millard and Steven Quinn from Novartis Australia. Kevin for his continued support and encouragement of all our projects; Helen for generously supporting and encouraging my travel to scientific meetings over recent years; and Steve for his genuine interest in my project, for bothering to understand the topic and for always managing to get hold of the paper I needed immediately (of course!), regardless of where he was, or what else he was doing at the time. I would also like to acknowledge the family of Melissa White (Melissa White Laboratory), Andrea, Michael and Ethan, for their tireless support over the last many years, both in the form of fundraising, but also for their genuine interest in our projects, and tangible excitement that my PhD was nearly there!

To my extended family and many friends, who never failed to ask how my PhD was going every time we met. Thanks for your support, and encouragement, even when you had no idea of what or why! To my mother, thanks for your support and continued love. I know right now, you are too unwell to really understand..but hopefully sometime in the future you will be able to celebrate the completion of this Thesis with me.

To my darling boys. As I write this, my 17 year old son Daniel is sitting his final Year 12 exams. My 11 year old son Matthew is reeling from living in a household where his brother and mother are incessantly staring at computers, and my husband Robert is seriously wondering what he said "yes" to! I thank you all for thinking this is "special". For tolerating my less than gracious moods at times, and for forgiving me when I just couldn't be there. I never would have got this far without your unconditional love and encouragement and for this I sincerely thank, and love you all. The great news is, as a family we have made it! A little battle weary maybe, but nothing a bit of time and TLC won't cure!

Finally, there are 4 people to whom I dedicate this thesis. Unfortunately, I have lost all of them over the last few years, but in my heart I know that they know, and I know just how proud they would be. To my dear mother in law Thelma, who from the time I met her trusted my judgement, and took great pride in all I achieved. I still remember the tears we shared when I showed you my enrolment acceptance, and your announcement to all and sundry that your daughter in law was going to be a Doctor! To my Grandparents, Phyllis and Bryce Parkinson, and my dear Auntie Gwennie. Thankyou for always encouraging me to strive for more, and never accept near enough, to be good enough. Your many words of wisdom will stay with me forever. I love and miss you all so much, and not a day goes by that you escape my thoughts...

*“Don’t wait for a light to appear at the end of the tunnel;
stride down there and light the bloody thing yourself!”*

Sara Henderson

“Real success is finding your lifework in the work that you love.”

David McCullough

*“It is the mark of an educated mind to be able to entertain a thought without
accepting it.”*

Aristotle

*“The outcome of any serious research can only be to make two questions
grow where only one grew before. “*

Thorstein Veblen

“If you think you can, you can. And if you think you can't, you're right.”

Mary Kay Ash

GLOSSARY

AKI	ABL kinase inhibitor
ALL	acute lymphoblastic leukaemia
AMN107	second generation kinase inhibitor - nilotinib
AP	accelerated phase
ATP	adenosine triphosphate
BC	blast crisis
BCR	breakpoint cluster region
bp	base pairs
C	celcius
CCR	complete cytogenetic response
CCyR	complete cytogenetic response
cDNA	complementary deoxyribonucleic acid
CE	clonal evolution
CHR	complete haematologic response
CML	chronic myeloid leukaemia
COS-1 cells	Transformed African Green Monkey Kidney Fibroblast Cells
CP	chronic phase
CV	coefficient of variation
DEPC	diethyl pyrocarbonate
DMSO	dimethyl sulphoxide
DNA	Deoxyribonucleic acid
dNTPs	deoxynucleotide triphosphates
DSB	double strand break
DTT	dithiothreitol
EDTA	ethylene diamine tetraacetate
FISH	fluorescent in situ hybridisation
Grb2	Growth factor receptor bound Protein 2

HBSS	Hanks Balanced Salt Solution
HLA	human leucocyte antigen
IFN-AraC	interferon- α plus low dose cytarabine
IMDM	Iscove's modification of Dulbecco's medium.
IPTG	Isopropyl- β -thio-galactoside
IRIS	International randomised study of interferon versus STI571
JAK	Janus Kinase
kD	kilo Dalton
L	litre
M	molar
M-bcr	major breakpoint cluster region
m-bcr	minor breakpoint cluster region
MCR	major cytogenetic response
MCyR	major cytogenetic response
MMR	major molecular response
mM	milli Molar (10^{-3} Molar)
MNC	Mononuclear cells
mRNA	messenger ribonucleic acid
μM	micro Molar (10^{-6} Molar)
μg	micro gram (10^{-6} gram)
ND	not detected
Ng	nano gram (10^{-9} gram)
PBS	Phosphate Buffered Saline
PCR	polymerase chain reaction
PCyR	partial cytogenetic response
PFS	progression free survival
Pg	pico gram (10^{-12} gram)
Ph	Philadelphia chromosome
Phe	Phenylalanine

PHR	partial haematologic response
PI3-K	Phosphatidylinositol – 3-kinase
PKA	cAMP- dependent protein kinase
PKC	Protein kinase C
P-loop	phosphate binding loop
QC	quality control
RNA	ribonucleic acid
RPMI	Roswell Park Memorial Institute (media)
RT-PCR	reverse transcription polymerase chain reaction
SD	standard deviation
SDS-PAGE	Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis
SH	Src homology
STI571	signal transduction inhibitor 571 (imatinib)
TKI	Tyrosine kinase inhibitor
Tyr	Tyrosine
U	units
UV	ultraviolet
v/v	volume per volume
WCC	white cell count
w/v	Weight per unit volume
y	year

Clinical Trials Referred to in this Thesis

TIDEL (CML6)

A Phase II study in adult patients with newly-diagnosed chronic myeloid leukaemia of initial intensified Glivec® therapy, and sequential combination therapy for non-responders.

The study involved an initial single arm of intensified dose imatinib (600mg), followed by a branching pattern of therapeutic options (acceleration to 800mg or combination of 600mg + AraC), determined by each patient's response.

TOPS (CSTI571K2301)

A randomized open-label study of 400mg versus 800 mg Gleevec/Glivec (imatinib mesylate) in patients with newly diagnosed, previously untreated chronic myeloid leukaemic in chronic phase (CP-CML) using molecular endpoints.

Patients were randomized 2:1 to the 800mg or 400mg treatments arms. Randomization into each arm was stratified by the Sokal score at entry into the study.

I am very grateful to the principal investigators and clinical trial coordinators within Australia and New Zealand who have provided clinical data, and samples from these Trials for the studies discussed in this Thesis.

Abstract

The natural history of CML has been transformed in recent years by the introduction of Glivec™ (imatinib mesylate), an ABL kinase inhibitor, which provides the new treatment paradigm for chronic phase CML. While the majority of patients with CP-CML respond very well to imatinib, there are approximately 15% of patients who fail to respond, or respond suboptimally. While the major cause of secondary imatinib resistance can be attributable to kinase domain mutations, the underlying cause of primary resistance is yet to be elucidated.

Utilizing the phosphorylation of the adaptor protein Crkl, an immediate downstream partner of BCR-ABL, as a surrogate measure of BCR-ABL kinase activity, a large interpatient variation in the degree of imatinib induced kinase inhibition achieved in-vitro, was observed in previously untreated CP-CML patients. The observed in-vitro sensitivity was a good predictor of molecular response in patients treated with 600mg imatinib as front line therapy. Furthermore, analysis of the in-vivo reduction in p-Crkl mediated measured in blood cells in response to imatinib over the first 28 days of therapy, revealed that patients with higher % reductions respond significantly better over a two year period, than those with lower % reductions.

Using 14-C labelled imatinib, it was demonstrated that this intrinsic sensitivity correlated to the amount of drug which was retained within the target haemopoietic cell, and furthermore, that a critical determinant of the active influx of imatinib, was the functional activity of the human organic cation transporter -1 (OCT-1), as determined by a prazosin (potent inhibitor of OCT-1) inhibition assay. Patients with high OCT-1 Activity had superior molecular responses when compared to those with low OCT-1 Activity, but in those patients who could tolerate increased imatinib dose, these inferior responses could be largely overcome. In contrast, Nilotinib, a more potent second generation tyrosine kinase inhibitor, is not dependent on OCT-1 for influx, making it a possible treatment choice for patients with low OCT-1 Activity.

Both imatinib and nilotinib interact with the efflux transporters ABCB1, and ABCG2. In combination studies imatinib results in a significantly increased intracellular concentration of nilotinib, most likely through interaction with these efflux transporters. Furthermore, commonly used therapies such as proton pump inhibitors also interact with ABCB1 and ABCG2, and demonstrable changes in

intracellular drug concentrations were observed in-vitro with concomitant administration of these agents and imatinib or nilotinib at clinically relevant concentrations.

In conclusion, these data demonstrate that the degree of kinase inhibition mediated in-vitro and in-vivo by imatinib, is a critical determinant of subsequent molecular response. This intrinsic sensitivity to imatinib induced kinase inhibition is related to the activity of the OCT-1 protein. This protein is not involved in the transport of nilotinib, suggesting it as a possible treatment alternative in those patients with low OCT-1 Activity.